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ABSTRACT 
 
Introduction 
 
The advent of potent anti-retroviral agents for HIV treatment has resulted in 
marked decrease in deaths. Health workers now have to ensure that their 
patient’s physical, social, and psychological well-being is optimized. This study 
used a validated tool to measure Health Related Quality of Life concepts 
amongst HIV patients in a public treatment program. The main objective of this 
research was to establish factors that are associated with poor quality of life of 
these patients with the purpose of using this information as a basis for 
determining who would require individualized medical care and attention. 
 
Materials and methods 
 
The study is set at Bontleng Clinic in Gaborone, Botswana. The study 
questionnaire consisted of two parts: part one for collecting data on socio-
demographic, illness and treatment related factors, and part two was the Medical 
Outcomes Study – Short Form tool used to obtain data on quality of life concepts. 
Two groups of participants were interviewed: ART-Naïve (n=90) and ART-
Experienced (n=110). The study protocol had ethical approval from both the 
University of the Witwatersrand, Johannesburg and the Ministry of Health in 
Botswana. 
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Results 
 
A smaller proportion of ART-experienced participants reported various disease 
symptoms as compared to those participants who were ART-naïve. Statistically 
significant differences were noted for: weight loss (25% vs 77%), diarrhoea (3% 
vs 11%), cough (19% vs 39%), and night sweats (24% vs 43%) for ART 
experienced and ART Naïve patients respectively. CD4 counts and HB levels 
were also significantly higher in patients on HAART. The overall QoL summary 
score was significantly higher (better) in the ART-experienced (mean score 53 
out of 100) compared to the ART-naïve group (mean score 47 out of 100). 
Therefore being on ART favoured a higher QoL score. However, changes in the 
three laboratory indices of CD4 count, Hb level, and viral load had no statistical 
significant association with HRQoL scores. Multiple regression identified only five 
factors as being associated with better QoL scores. These factors were to do with 
the absence of the following disease symptoms: weight loss, diarrhoea, night 
sweats, and feet pains; as well as absence of recent hospitalisation.   
 
Discussion 
 
The study patients do respond well to HAART with significant improvements in all 
dimensions of QoL. This is in keeping with findings from other populations. In 
assessing these patients at the initiation of HAART, and at subsequent visits, one 
must take into account any history of recent hospital admission, history of weight 
loss, and most importantly presence/absence of various disease symptoms.  
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Conclusions and recommendations 
 
Symptoms, regardless of the underlying cause: be it due to HIV disease itself or 
drug side effects; greatly impact patients’ quality of life. Efforts should be made to 
include the assessment of symptoms in the continuum of care of HIV patients. 
The introduction of newer potent anti-retroviral agents with fewer side effects 
should also favour the beneficial impact of HAART. 
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Introduction 
Definition of Quality of Life:  
 
Last (22) gives a straight forward definition of Quality of Life as the degree to 
which persons perceive themselves able to function physically, emotionally, (and) 
socially. 
 
Mallory et al (4) has a more detailed definition of Health Related Quality of Life as 
a ‘multi-dimensional construct that refers to how well an individual functions in 
daily life and perceptions of how health status influences his or her life. 
 
Quantitative assessments of Quality of life (QoL) are commonly used in clinical 
trials that compare different study arms. QoL measurements in such studies help 
identify and compare toxicities, or side effects of the competing therapies or 
interventions. Outside the scope of clinical trials, information on quality of life can 
also be useful in determining who amongst a large group of patients in a 
treatment program (e.g. for HIV) would require individualized attention and 
tailored treatment options for optimal response. This later goal is the focus of this 
research paper. 
 
Factors previously identified as affecting QoL for HIV patients include: low CD4 
count, hospitalization before enrollment, presence of symptoms, and 
dissatisfaction with information given by care giver(1) . Some factors associated 
with improved QoL are: short length of time since HIV diagnosis, undetectable 
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viral load after 12 months of being on ARVs, and a low number of reported 
symptoms(2). 
 
It is vital to identify factors and characteristics that play a role in determining the 
overall quality of life among HIV patients, as these factors will ultimately influence 
the uptake, adherence, and ultimately response to ARV therapy. 
 
 
 
Background 
  
Health Related Quality of Life (HRQoL) in the context of HIV/AIDS patients refers 
to how a person living with HIV/AIDS is satisfied with his or her life as a whole (3). 
The aim of this rapidly expanding branch of medical science is to use specific 
indicators to measure, compare and ultimately optimize the physical, social and 
psychological wellbeing of patients on different therapies or interventions.  
 
HIV therapies are complex with many associated side effects as the disease 
follows a protracted course. The need to incorporate HRQoL in the assessment 
of these therapies, as is being done with therapies for other chronic illnesses 
such as cancer and arthritis, is now well recognized (5).  
 
In January 2002 the Government of Botswana instituted the Masa (Setswana for 
‘dawn’ of a new day) Program whose aim is to provide free antiretroviral 
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treatment to all qualifying citizens. By July 2004 the program had registered over 
17000 patients. To enroll in this program one has to be HIV-positive with a CD4 
cell count of ≤ 200/µL or with an AIDS defining illness (24). Currently there are 
more than 20 sites country-wide where this program is being implemented. 
 
Universally access to ARV treatment is all but inevitable under this rapidly 
expanding program. Currently patient survival rate is the routine measure of 
success of the program. This researcher believes that quality of life data should 
now also be routinely obtained and used to monitor and evaluate the Masa 
program.  
 
 
Literature Review 
 
The 2005 official Botswana Government statistics (7) put the HIV prevalence at 
33.4% of all pregnant women seeking ante-natal services. It is estimated that 
over 250,000 adults in Botswana are HIV positive (7), and these people will 
require Highly Active Antiretroviral Treatment (HAART) in the next few years. 
 
Studies in Botswana have documented excellent clinical and virological response 
to HAART in HIV patients, though with high rates of toxicity with certain anti-
retroviral drug regimens (8). Unfortunately very few studies have been performed 
in Africa to assess health-related quality of life amongst people living with 
HIV/AIDS, and very little is documented on how ARV therapy impacts on patient’s 
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quality of life as measured from the patient’s own perspective. Studies on HRQoL 
will help in advancing the additional treatment goals of avoiding drug related 
toxicity and improving adherence in the long term (9). 
 
R. Murri et al (1) looked at a cohort of Italian HIV patients in a multi-center study 
and identified the following: 
 
 At baseline the predictors of poor HRQoL were:  
Low CD4 count,  
Hospitalization during the past three months and, 
Presence of symptoms. 
At six months the predictors of HRQoL were:  
Stage of HIV infection,  
Baseline CD4 count and,  
Symptom score. 
 
Current guidelines on anti-retroviral therapy (10) are based on the principle of 
aggressive initial treatment to reduce viral load which is then followed by long 
term treatment to suppress viral replication. The issues of side effects during long 
term use of ARVs is coming to the fore as we move from rescuing patients from 
the brink of death to long-term maintenance with an expectation of high quality of 
life (9).  
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As previously noted, use of ARVs in the public domain is now well established in 
Botswana; however drug toxicity, especially peripheral neuropathy, is a noted 
feature in some patients. One study (8) reported that close to 24% of Botswana 
patients experience severe toxicities before the end of the first year on ARVs. 
The issue of drug side-effects significantly affecting patient’s quality of life has 
been noted in several studies (4) (5) (11). 
 
HRQoL measurements are now being utilized in greater frequency in clinical 
trials and in quality of care studies. Many different tools have been developed to 
measure HRQoL. In this study the researcher will utilize the MOS-SF survey tool 
which has been utilized in several studies (12) (13) (5) and found to be a reliable 
and valid measure of quality of life for patients with HIV infection. 
 
Below is a summary of results of two studies on HRQoL to serve as a comparator 
to this study. The first study is located in a developed country (United States of 
America), and the second one is a recent study in a developing country (South 
Africa). 
 
U.S.A*: Factors associated with lower HRQoL in HIV infected persons (20). 
• Older age 
• Female sex 
• Black or Hispanic race/ethnicity 
• Injection drug use 
• Lower education and income 
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• No private health insurance 
• Lower CD4 count. 
 
South Africa**: Comparing HAART and Non-HAART HIV positive patients (21): 
• HAART patients were twice more likely to have a higher HRQoL index 
than non-HAART patients. 
• Employed respondents were more likely to have a higher HRQoL than 
unemployed respondents (though this was not statistically significant). 
 
Study Aim 
The study had the following aims: 
• To identify socio-demographic and laboratory factors that are associated 
with poor or high health-related quality of life in patients enrolling for anti-
retroviral therapy in Botswana.  
• To investigate if anti-retroviral therapy has any association with improved 
quality of life.  
• To demonstrate and promote the use of HRQoL instruments in the initial 
work-up and subsequent follow-up of patients in public ARV therapy 
programs in Africa.  
 
 
* Taking antiretroviral medication was not associated with differences in HRQoL regardless of CD4 count. Median age of 
study participants was 37 years. 
** 75% of the South African interviewees were aged below 45 years, with twice as many women than men. 
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Study Objectives 
The objectives of the study are: 
 
1. To describe two groups of patients: those about to go on ART, and those 
who have been on treatment in terms of: 
 
a. Socio-demographic factors, and  
b. HIV disease markers (CD4 count, Viral load, hemoglobin level) 
  
2. To measure HRQoL in a sample of patients as they start ARV treatment 
(‘ART Naïve’), as well as a sample of patients who have been on treatment 
for at least six months (‘ART Experienced’), at a public HIV treatment site 
in Gaborone, Botswana. 
 
3. To determine factors associated with HRQoL by comparing treatment 
status, socio-demographic characteristics and disease markers (latest 
available laboratory HIV monitoring data) with HRQoL scores. 
 
4. To investigate any association between HRQoL and the following HIV 
patient factors: patient satisfaction, illness-related factors, disease-related 
factors, and symptoms 
 
 
 
  
8 
METHODS 
A. Study design 
This was a cross-sectional comparative study involving simultaneous primary 
data collection of explanatory and outcome variables in two distinct groups of 
participants.  
HRQoL (outcome) and data on various predictor (explanatory) factors was 
measured in the following two groups of participants: 
 
1. ART Naïve Group: This group consisted of participants who were eligible 
for Anti-Retroviral Treatment but had not yet commenced the treatment. 
This group were still undergoing administrative processes before starting 
HIV treatment. 
  
2. ART Experienced Group: This group consisted of participants who had 
been on ARV medications for 6 or more months by the date the researcher 
was conducting the HRQoL interview. 
 
B. Study population  
The study population consisted of adult Botswana citizen HIV positive patients 
attending a public HIV treatment site in the city of Gaborone, Botswana.  
 
Study participants would either be new patients qualifying for, and presenting 
themselves for the first time for ARV treatment, OR old patients already taking 
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ARV treatment for 6 or more months at the time the researcher was undertaking 
this study.  
 
C: Principles of HRQoL Measurement (6) 
HRQoL measurements objectively document issues like treatment toxicity and 
psychological aspects of illness such as anxiety or depression, ability to cope 
with illness, and satisfaction with life. Many generic instruments have been 
developed to measure HRQoL, and all use fairly simple forms of scoring. 
 
Examples of QoL measurement tools include (6): Nottingham Health Profile 
(NHP), EuroQol (EQ-5D), Functional Assessment of Cancer Therapy (FACT-G), 
Quality of Life in Epilepsy (QOLIE-89), and the McGill Pain Questionnaire (MPQ). 
In general a change of 5 – 10 points on a 100-point scale is regarded as 
significant and likely to be noticed by the patients 
 
HRQoL is essentially measured by interviewing only the patient. This is because 
observers such as relatives or health care workers are known to dwell on obvious 
symptoms while under-estimating the impact of psychological aspects of a 
disease on the patient. Conventional clinical outcomes also correlate poorly with 
patients’ own assessment of their quality of life.  
 
 
The Medical Outcomes Study for HIV Short Form (MOS-SF) health survey 
instrument that is used in this study consists of patient self-ratings on 20 items 
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measuring 6 health concepts (see Appendix B-2): Physical functioning, Role 
functioning, Social functioning, Mental health, Health perceptions, and Pain. 
 
Table 1 below gives a brief description, in terms of meaning, of the 6 Medical 
Outcomes Study construct scales. 
 
 
Table 1. Summary of MOS-HIV Survey Concepts 
 
Concept No. of Items in 
Questionnaire 
Meaning of a Low score Meaning of a High score 
Physical Functioning 
 
6 
 
Very limited in performing 
physical activities due to 
poor health including eating, 
dressing, bathing or using 
the toilet 
 
Performs all types of physical 
activities due to poor health 
including vigorous or 
strenuous activities without 
limitations 
 
Role Functioning 
 
2 
 
As a result of physical 
health, experiences 
problems with work or daily 
activities 
 
No problems with work or 
other daily activities as a 
result of health 
 
Social Functioning 
 
1 
 
Social activities limited due 
to health 
 
No limitations on social 
activities as a result of health 
 
Mental Health 
 
5 
 
Feels nervous and depressed 
all of the time 
 
Feels calm, peaceful and 
happy all of the time 
 
General Health 
Perceptions 
 
5 
 
Views personal health as 
poor 
Views personal health as 
excellent 
 
Pain 
 
2 
 
Very severe and limiting 
pain 
No pain or limitations due to 
pain 
 
Note: Adapted from “The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and 
item selection” by J.E. Ware and C.D. Sherbourne, 1992, Medical Care, 30: 473-483. 
 
Two summary scores are then obtained by use of formulae (see Appendix A):  
1. PHS - Physical Health Summary score and  
2. MHS – Mental Health Summary score, 
For purpose of this study we will examine only the PHS.  
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D. Sample size calculation  
 
Sample size calculation(14) 
It was important to do a sample size calculation for this study so that if in actual 
fact there was a difference in HRQoL in our two study groups, this study should 
have been able to detect that difference and that the analysis would be 
statistically significant. 
 
The researcher did the actual sample size calculation using STATA® computer 
statistical program. 
 
The variables of interest were:  
 
1. The desired power i.e the probability that the null hypothesis will be 
correctly rejected. A power of 90% was set. 
2. The desired significance level i.e the cut-off point for the p-value below 
which the null hypothesis would be rejected. This level was set at 5%. 
3. Size of difference of HRQoL scores of clinical importance = 5 points 
4. The standard deviation of HRQoL was estimated at 10 points 
5. The primary outcome variable was HRQoL scores summarized by means 
 
. sampsi 45 50, p(0.9) r(1) sd1(10) sd2(10) 
 
Estimated sample size for two-sample comparison of means 
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The Null hypothesis was that mean HRQoL in ART-Naïve patients = mean 
HRQoL in ART-Experienced patients. 
 
Assumptions: 
 
         alpha =    0.0500  (two-sided) 
         power =   0.9000 
            m1 =     45 (estimated mean QoL score for ART-naïve group) 
            m2 =     50 (estimated mean QoL score for ART-experienced group) 
           sd1 =     10 (estimated standard dev for ART-naïve group) 
           sd2 =     10 (estimated standard dev for ART-experienced group) 
         n2/n1 =    1.00 (ratio of participants in experienced to naive) 
 
Estimated required sample sizes: 
 
            n1 =       85 (sample size in ART-naïve group) 
            n2 =       85 (sample size in ART-experienced group) 
 
. 
Thus minimum sample size per group = 85 per group, 170 in total. 
The researcher decided to increase this number by 18% to 200 participants to 
cover for any participants who might otherwise withdraw their consent or drop out 
once enrolled. 
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E. Sampling method 
The ART clinic attends patients on a first come first served basis. Clinic staff 
ensure patients are seated in a waiting area in their order of arrival. The clinic 
operates only weekday mornings. Patients arrive early morning (almost as a 
group), and by midday they have all been attended to and gone. 
 
The research assistant would first give an overview presentation of the study to 
all patients seated in the waiting room. She would then invite anyone interested in 
the study to see her (one by one in order of the clinic queue) in a side room just 
adjacent to the general waiting area. 
 
She would explain the study in more detail to those who were interested and had 
come in to see her. She would politely decline to interview those who did not 
meet this study’s selection criteria.  All interviews went well and did not take 
much of the patients’ time as they were all able to regain their spots on the 
original clinic queue. 
 
This was thus a non-random sampling procedure as only interested and self-
selecting consecutive persons participated. Thus those who consented to 
participate were included into the study until the required numbers were reached 
(15).  
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ART-naïve patients’ first attendance to the clinic is without appointment, and the 
researcher interviewed them before they got registered into the clinics’ computer 
database. The researcher thus did not have a sampling frame by which random 
sampling would have been achieved. 
 
F. Data collection 
 
Training:  
The researcher trained one research assistant on principles of health research 
and on use of a structured questionnaire for data collection, with emphasis on 
ethical considerations. Specific training was then done on the nature and reason 
of the study, and how to collect the data, including questionnaire administration 
(both questionnaires in Appendices B-1 and B-2 were administered) and 
examination of a participant’s clinic records for information on CD4 count, Hb 
level, and VL. 
 
Pilot testing:  
This was conducted on 5 members of the community. It was done to ensure the 
research assistant understood the purpose and meaning of each item in the 
questionnaire so that she could be able to elicit meaningful responses from 
respondents. Piloting also tested the flow of the questionnaire and clarity of each 
question. 
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Interviews: 
These were conducted at Bontleng Clinic from April 2007 to June 2007. As noted 
earlier, the research assistant would first give a short presentation about the 
study to potential participants as they sat in the waiting room of the clinic. 
Interested participants would then present themselves one at a time into a quiet 
side room where the interviewer was seated and their privacy was assured.  
 
The purpose of the study, and how the interview was going to be conducted, 
would then be further explained. At this stage all participants who consented to 
being interviewed would then be asked to sign the informed consent form before 
proceeding with the interview. Interviews took about 20 minutes to complete with 
the research assistant reading out the structured questionnaire and filling it in as 
per responses received. Clinic staff then availed the research assistant with the 
participant’s file for extraction of latest recorded laboratory data. 
 
At the time this study was conducted public ART services in Gaborone were only 
being offered at the City’s main Government hospital (Princess Marina Hospital) 
and at Bontleng Council Clinic. Thus at that time these patients did reflect a fair 
representation of the city residents who accessed public ART programmes. 
Currently (2008) ARV services in the City have been expanded and three other 
public clinics in the City of Gaborone do offer ART services. 
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G. Data management and quality 
 
The researcher actively supervised data collection and did sit in on some 
interviews for quality checks. 
 
Completed questionnaires were reviewed daily by the researcher and discussed 
with the research assistant to ensure responses had been accurately, completely, 
and correctly captured. There was thus no incident of missed data. The following 
amendments were made: 
 
1. Q3 length of time on ARVs was converted into total time in months. 
2. Q4 on employment status was re-coded to two variables only: 
Unemployed or Employed (to include all those having regular jobs or 
temporary jobs or are self employed), as it proved difficult to get accurate 
responses for the initial 4 response sub-categories. 
3. Q9 on education level was re-coded into the following four categories: 
none/primary/secondary/tertiary. 
4. Q10 the research assistant found it difficult to convert a respondent’s 
work/vocation into a skill level, she thus just wrote down the exact vocation 
and the researcher then later converted these entries into a skill level. 
5. Q11 asks about number of years since HIV diagnosis, we converted the 
question and the responses to obtain number of months instead of years. 
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6. Q25 on disease symptoms is ‘none of the above’, we converted this to 
‘Other symptoms’ as participants mentioned many other symptoms such 
as dizziness, back pains, headache, chest pains, body itchiness, etc . 
7. An unexpected finding was that all ART-naïve patients did not have record 
of their Viral Load as that test had not been done. We coded and entered 
this into the data base using the word ‘blank’ rather than numerical ‘0’ 
which would have caused confusion. In general, after a period of being on 
ART, Viral Load levels are expected to decrease as compared to baseline 
levels. This researcher would have liked to find out if any changes in VL 
are associated with changes in HRQoL in this population. However, a 
review of other studies (22) shows that presence (or paucity) of VL data 
was unlikely to affect the outcome of this study. 
 
The researcher then went through each questionnaire and coded the responses 
by writing the corresponding code in pencil next to each response. 
 
The researcher then created an Excel® spreadsheet that contained all the 
variables in the questionnaire. Double data entry was done with the research 
assistant doing initial entry, while the researcher did the second verification entry. 
 
Visual inspection of the entered data was done. Range checks for consistency 
were also done using the Excel® software. Data cleaning was then done by re-
checking inconsistent data with what was in the questionnaire.  
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Formulae (as detailed in Appendix A) obtained from Dr A. Wu’s handbook (16) 
were then entered into the Excel® database and executed to obtain scores for all 
the six QoL constructs, as well as to obtain the final summary PHS values for 
each participant. 
 
The process of obtaining item scores essentially transforms and averages each 
item to a 0 – 100 range of lowest to highest possible scores. The six items are 
then aggregated and weighted using the PHS formula to obtain a single summary 
QoL score. 
 
The data was then imported for statistical analysis into STATA® Version 9 using 
Statransfer® software. Variable labels where created for each variable in 
STATA® in order to ease understanding during analysis. 
 
 
H. Data Analysis  
 
The outcome variable measured in this study is health-related quality of life as 
indicated by the summary value Physical Health Score (PHS). Data analysis was 
done based on the objectives of the study. Table 2 on the following page gives a 
summary of variables investigated. 
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Table 2: Summary of study variables 
 
Variable Type Variable Category Variable 
 
 
Socio-economic factors 
Gender 
Age  
Marital status 
Work skills 
Employment status 
Education level 
 
 
 
 
Illness related factors 
Time (months) on ART 
Concurrent TB treatment 
Using isoniazid tabs (IPT) 
Prior TB treatment 
Relation to home care-r 
Recent hospitalization 
Time from HIV diagnosis 
Self OTC supplements 
 
 
Patient satisfaction 
 
With info given 
With care given 
 
 
 
 
Disease symptoms 
Weight loss 
Diarrhea 
Cough 
Difficulty in breathing 
Night sweats 
Feet pains 
Fever or chills 
Other symptoms  
 
 
 
 
 
 
 
 
 
 
Explanatory 
 
 
Laboratory markers 
Hemoglobin level 
CD4 cell count  
Viral Load 
 
 
 
 
       Outcome 
(numerical continuous 
variable) 
Health-related Quality of 
Life 
Physical fx 
Role fx 
Social fx 
Mental hlth 
Hlth perc’p. 
Pain 
  
PHS - 
Physical 
Health  
Score  
(derived 
summary) 
 
 
During statistical analysis a significance level of p < 0.05 was used throughout.  
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Data analysis sequence 
 
The following sequence was used during data analysis: 
1. Frequency tabulations was obtained for the following categorical variables: 
Marital status, work skills level, employment status, education level, 
presence of a caregiver, satisfaction levels for information and care, and 
presence of symptoms. 
2. Means, medians and ranges of the following numerical continuous 
variables obtained: 
Time on ARVs, time since HIV diagnosis, Viral Load levels, CD4 levels, Hb 
level, summary HRQoL scores. 
3. The above two were used to give descriptive statistics of the data. These 
are shown in tables 3, 4, 5, 6, and upper part of table 7. 
4. Un-paired t-tests were done to compare numerical continuous data of the 
two study groups. These are shown in lower part of table 7, and table 8. 
5. Chi-square tests to compare proportions of categorical variables of the two 
study groups. P-values obtained are shown in tables 3, 4, 6, and upper 7. 
6. Prior to using parametric tests to analyse the summary Physical Health 
Score (PHS). The distribution of this score was thus investigated for 
normality by visual inspection of its Histogram, Box Plot, and of its 
Normality plot (pnorm in Stata). The assumptions of normality were met. 
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7. Univariate analysis was then done on each variable, with the use of 
‘dummy’ variables during the Univariate analysis of categorical variables. 
Results are indicated in tables 9, 10, 11 and 12. 
8. Variables that were statistically significantly associated with QoL on 
Univariate analysis were then considered for inclusion in the multivariate 
model. 
9. Stepwise multivariate regression was then done using the method of least 
squares, starting with an empty model and adding significant Univariate 
variables one by one. The purpose of this was to obtain a model that 
would best explained QoL scores in these participants. This is shown in 
table 13. 
 
I. Ethical Considerations 
 
Approval 
The study protocol was reviewed and approved by both the Human Research 
Ethics Committee (Medical) of the University of the Witwatersrand, Johannesburg 
(Protocol Clearance Certificate Number M060541), and the Health Research & 
Development Committee of the Ministry of Health, Botswana (Reference No. 
PPM&E 13/18 PS Vol I (13) of February 21, 2006 and (55) of March 20, 2007). 
Further permission to collect the data at Bontleng clinic was obtained from the 
Chief Medical Officer, Gaborone City Council Clinics Department. Copies of 
these documents are available at Appendices D, E-1, and E-2.  
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Consent 
Patients were not coerced to participate in the study, and they were neither 
promised nor given any incentives. Signed informed consent was obtained from 
the participants before they were interviewed. Interviews were conducted in total 
privacy and anonymity was assured. Questionnaires were identified only by 
numbers and responses were kept confidential and not provided even to the 
clinic staff. 
Feedback 
Some participants did request for feedback of the study findings. Once the study 
is over the researcher and his assistant will go back and do presentations of the 
study findings to the patients at Bontleng Clinic.  
 
RESULTS  
 
Response rate  
This was low with the interviewer only managing to interview an average of 6 out 
of 50 eligible clinic attendees daily (12%).A total of 200 participants were 
interviewed. Accruing this number of participants took three months, from April to 
June 2007. Two reasons were given for refusal to participate: 
• Previous researchers from other studies did not provide them with 
feedback, so they did not see the need to assist this researcher. 
• They were just not interested in participating this study. 
The researcher did not collect information of socio-demographics of those who 
refused to participate in this study. 
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A. Descriptive Tables 
 
Table 3: Socio-Demographics of ART-naïve and ART-experienced patients in a 
QoL study in Botswana. 
 
 
FACTOR 
ART Naïve  
n (%). 
Total= 90 
ART Experienced n 
(%). 
Total = 110 
 
P-Value 
Gender 
   Male 
   Female 
 
41 (46) 
49 (54) 
 
39 (35) 
71 (65) 
0.147 
 
 
 
Age (years) 
   Mean 
    
 
35 
 
 
36 
 
 
0.3266 
 
Marital status 
   Married 
   Co-habiting 
   Single 
   Other 
 
  9  (10) 
27  (30) 
49  (54) 
  5  (6) 
 
16  (15) 
21  (19) 
65  (59) 
  8  (7) 
0.213 
Work skills 
   None 
   Semi-skilled 
   Trade skill 
   Professional 
 
65  (56) 
15  (23) 
  8  (14) 
  2  (4) 
 
67  (61) 
25  (23) 
15  (14) 
  3  (3) 
0.409 
Employment 
   Working 
   Unemployed 
 
47  (52) 
43  (48) 
 
81  (74) 
29  (26) 
0.002 
Education level 
   None 
   Primary  
   Secondary 
   Tertiary 
 
12 (13) 
36 (40) 
37 (41) 
  5 (6) 
 
  9 (8) 
39 (35) 
56 (51) 
  6 (5) 
0.467 
 
Table 3 above shows that the mean age is mid-thirties for both ART-experienced 
and ART-naïve groups. The greater proportion in both groups are either single 
(54%, 59%) or cohabiting (30%, 19%). Most respondents do not have any work 
skills (56%, 61%). There is a statistically significant association between the two 
variables (treatment and employment status) as the proportion of those on 
treatment who are working is (74%) compared to those not on treatment (52%).   
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Table 4: Comparison of Illness related factors 
 
FACTOR ART  
Naïve n(%). 
Total= 90 
ART Experienced 
n(%). 
Total = 110 
 
P-Value 
Time (months) on 
ARV treatment 
   Mean 
   Median 
   Range 
 
 
0 
0 
0 
 
 
20 
17 
6 – 149 
 
 
- 
If currently on TB 
treatment 
   Yes 
   No 
 
 
18(20) 
72(80) 
 
 
28(25) 
82(75) 
 
0.362 
If currently on TB 
prevention treatment 
(IPT) 
   Yes 
   No 
 
 
 
52(58) 
38(42) 
 
 
 
74(67) 
36(33) 
 
 
0.166 
If previous history of 
TB treatment 
   Yes 
   No 
 
 
11(12) 
79(88) 
 
 
13(12) 
97(88) 
 
0.930 
Caregiver (treatment 
buddy) 
   Close family 
   Other relative 
   Friend 
   Other 
   None 
 
 
50(56) 
21(23) 
13(14) 
  4(4) 
  2(2) 
 
 
76(69) 
26(24) 
  8(7) 
  0(0) 
  0(0) 
 
0.024 
Hospitalisation in past 
3 months 
   Yes 
   No 
 
 
12(13) 
78(87) 
 
 
14(13) 
96(87) 
 
0.899 
Time (months) from 
Diagnosis to starting 
ARVs 
      Median 
      Range 
 
 
 
7.5 
0 - 93 
 
 
 
26 
2 - 149 
 
 
- 
If uses other 
‘supplementary’ 
products 
   Yes 
   No 
 
 
 
13(14) 
77(86) 
 
 
 
    8(7) 
102(93) 
 
 
0.100 
‘Supplementary products’: are self-prescribed over the counter nutritional, herbal, or vitamin products that patients 
purchase by themselves. 
 
Table 4 above shows there is no statistical association between the two variables 
cross tabulated (being on ART and being on TB treatment) as there is no 
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difference in proportions of those currently taking tuberculosis treatment between 
the two groups (20% vs 25% for ART-experienced and ART-naïve patients 
respectively).The exact same proportion (12%) in the two groups has previously 
been on TB treatment. Significantly, more patients in the ART-experienced group 
have a close family member as a caregiver (treatment supporter) (69%), 
compared to 56% in the ART-naïve group. Surprisingly, exactly the same 
proportion in the two groups (13%) has been hospitalized in the previous three 
months. Very few patients report use of ‘supplementary products’ (14% and 7% 
for ART-experienced and ART-naive groups respectively). 
 
Table 5: OTC Supplements being used by ART-naïve and ART-experienced 
groups. 
 
ART naïve group 
 
ART experienced group 
African Potato 
B-Immune Meal 
Cannova Drops 
Go-for-Health 
Green Tea 
Nutri Powder 
Selenium 
Tesly Tablets 
 
African Potato 
Bio-viusid 
Calcivita 
Chinese Tea 
Go-for-Health 
Golden Products 
Green Tea 
Selenium 
 
 
Table 5 above shows that the range of over the counter supplementary products 
used by participants appears to be the same in the two groups. 
 
 
 
 
 
 
 
 
 
 
 
  
26
 
 
 
 
 
Table 6: Patient satisfaction with information and care in ART-naïve and ART-
experienced patients. 
 
 
Satisfaction Level 
 
ART  
Naïve n(%). 
Total= 90 
 
 
ART Experienced 
n(%). 
Total = 110 
 
p-value 
 
Information given 
   
  Not satisfied 
  Low satisfaction 
  Mod. satisfaction 
  High. Satisfaction 
 
 
 
 
  0 (0) 
  3 (3) 
30(33) 
57(63) 
 
 
 
  2(2) 
  0(0) 
18(16) 
90(82) 
 
0.004 
 
Care given 
   
  Not satisfied 
  Low satisfaction 
  Mod. satisfaction 
  High. Satisfaction 
 
  
 
 
 
 
 1(1) 
 1(1) 
20(22) 
68(76) 
 
 
 
  1(1) 
  3(3) 
18(16) 
88(80) 
 
0.640 
‘Information given’ refers to if and how health care workers give information to patients about their illness, ‘Care given’ 
refers to the full treatment package received including counselling, lab work, medicines, etc. 
 
Table 6 above shows that most patients are highly satisfied with the information 
and care they receive from the clinic. A statistically significant association is 
noted between the cross tabulated variables (being on ART and reporting high 
satisfaction with information) as a higher proportion of ART-experienced reports 
high satisfaction with information given (82%) compared to ART Naïve group 
(63%). 
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Table 7: Comparison of disease symptoms and disease markers between ART-
experienced patients and ART-naive patients. 
 
 
Symptom / Marker  
 
ART  
Naïve n(%). 
Total= 90 
 
 
ART Experienced n(%). 
Total = 110 
 
p-value 
 
Loss of weight 
Diarrhea 
Cough 
Difficulty in breathing 
Night sweats 
Feet pains  
Fever or chills 
Other symptoms 
 
 
 
69 (77) 
10 (11)  
35 (39) 
22 (24) 
39 (43) 
50 (56) 
31 (34) 
37 (41) 
 
 
 
27 (25) 
  3 (3) 
21 (19) 
17 (15) 
26 (24) 
52 (47) 
32 (29) 
39 (35) 
 
 
 
0.000 
0.017 
0.002 
0.110 
0.003 
0.244 
0.372 
0.366 
 
 
Viral Load (copies/ml) 
   Mean 
   Median  
   Range 
   SD 
 
CD4 (cells/ml) 
    
Mean 
    
Hemoglobin (g/dl)  
    
Mean 
 
 
 
No data 
No data 
No data 
No data 
 
 
 
114 
 
 
 
8.9 
 
 
 
11397 
400 
400 – 750,000 
75295 
 
 
 
276 
 
 
 
10.9 
 
 
 
- 
 
 
 
 
 
 
0.000 
 
 
 
0.000 
 
 
Table 7 above shows statistically significant higher proportions of ART-naïve 
patients report having loss of weight (77% to 25%), diarrhea (11% to 3%), cough 
(39% to 19%), and night sweats (43% to 24%) for ART-naive and ART-
experienced patients respectively. There is no data on VL in the ART-naïve 
group. The ART experienced group has a median VL of 400 copies/ml. Mean 
CD4 counts and Hb levels were significantly higher in ART- experienced 
individuals compared to ART-naïve individuals.   
  
28
 
 
 
 
TABLE 8: Scores for HRQoL constructs and overall PHS summary  
[note: higher score indicates a more favorable quality of life] 
 
Quality of Life 
Construct 
ART Naïve group  
 
Mean Score (%) 
ART 
Experienced group 
Mean score (%)  
P-value  
 
Physical Functioning 
 
Role Functioning 
 
Social Functioning 
 
Mental Health 
 
Health Perception 
 
Pain 
_________________ 
 
SUMMARY SCORE 
(PHS – Physical Health 
Summary) 
 
 
80 
 
82 
 
84 
 
67 
 
45 
 
43 
___________ 
 
47 
 
 
 
89 
 
87 
 
91 
 
72 
 
60 
 
63 
___________ 
 
53 
 
 
 
0.0002 
 
0.1361 
 
0.0440 
 
0.0110 
 
0.0000 
 
0.0016 
________ 
 
0.000 
 
Table 8 shows the ART-experienced group scores are statistically significantly 
higher (better) for all HRQoL constructs except for Role Functioning where the 
score for ART Experienced is still higher (87% compared to 82%) but not 
significantly so. Overall summary score is statistically significantly higher in ART 
Experienced patients (63% compared to 47%). 
It is interesting that ART-experienced patients score high on all constructs except 
for Role Functioning (problems with work or daily activities). This effect may be 
real, or perceived as a result of being on chronic medication. An alternate 
explanation may be that this construct is probably only affected by extremely 
debilitating disease or a late stage of untreated HIV disease. 
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B. Univariate and Multivariate Models 
 
Table 9: Univariate and multivariate regression models for baseline Socio-
demographic factors associated with QoL for HIV patients in Gaborone 
 
 
FACTOR 
Univariate Model 
Coeff.(95% ci)  p-value 
Multivariate Model adjusted for Treatment Group 
Coeff.(95% ci)  p-value 
Gender 
Male       
Female 
 
 
Ref. 
1.93 (-0.64 –  4.51) 0.140   
 
Variable not significant 
 
 
 
Age 
 
-0.11 (-0.27 – 0.06) 0.212 
 
 
Variable not significant 
Marital status 
Married 
Co-habiting 
Single 
Separated 
 
 
Ref. 
1.54 (-2.86 – 5.93) 0.491 
2.88 (-1.06 – 6.82) 0.150 
8.87 (0.77 – 16.97) 0.032 
 
 
Ref. 
2.57 (-1.69 – 6.83) 0.235 
3.24 (-0.56 – 7.02) 0.094 
7.88 (0.07 – 15.70) 0.048 
 
Work skills 
None    
Semi-skilled 
Trade skill 
Professional 
 
 
Ref. 
1.13 (-2.10 – 4.37) 0.491 
2.52 (-1.53 – 6.57) 0.222 
4.14 (-4.03 – 12.30) 0.319 
 
Variable not significant 
 
 
 
 
 
Employment 
   Working 
   Unemployed 
 
 
Ref. 
-1.75 (-4.38 – 0.88) 0.192 
 
Variable not significant 
 
 
Education level 
   None 
   Primary  
   Secondary 
   Tertiary 
     
 
Ref. 
2.97 (-1.40 – 7.34) 0.182 
5.38 (1.10 – 9.66) 0.014 
4.74 (-1.86 – 11.33) 0.158 
 
 
Ref. 
2.52 (-1.70 – 6.75) 0.240 
4.53 (0.38 – 8.68) 0.032 
4.16 (-2.20 – 10.53) 0.199 
 
Treatment Group 
ART-naïve 
ART-experienced 
 
 
Ref. 
5.22 (2.77 – 7.66) 0.000 
 
Ref. 
5.22 (2.77 – 7.66) 0.000 
 
Table 9 above indicates there was a statistically significant difference in QoL 
scores between married individuals and those who were separated – with 
separated individuals having 7.88 points higher QoL scores than individuals who 
were married. Participants who had some secondary education had QoL scores 
that were on average 4.53 points higher than those who never went to school. 
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Other factors: gender, age, work skills level and employment status were not 
statistically associated with QoL scores.  
Table 10: Univariate and multivariate regression models for Illness related factors 
that are associated with QoL for patients on ART in Gaborone.  
 
 
FACTOR 
Univariate Model 
Coeff. (95% ci) p-value 
Multivariate adjusted for 
Treatment Group 
Coeff. (95% ci) p-value 
 
Time on ART  
 
 
0.075 (-0.00 – 0.16) 0.063 
 
 
Variable not significant 
 
Presently on TB 
treatment 
   Yes 
   No 
 
 
 
Ref 
1.07 (-1.94 – 4.08) 0.484 
 
Variable not significant 
 
 
Presently on TB 
prevention (IPT) 
   Yes 
   No 
 
 
 
Ref 
-1.40 (-4.02 – 1.23) 0.295 
 
Variable not significant 
 
 
Treated for  
TB before 
   Yes 
   No 
 
 
 
Ref 
-1.05 (-4.96 – 2.85) 0.595 
 
Variable not significant 
 
 
 
 
Caregiver 
(treatment ‘buddy’) 
   Close family 
   Other relative 
   Friend 
 
 
 
Ref 
-0.79 (-3.86 – 2.29) 0.615 
0.93 (-3.30 – 5.16) 0.665 
 
Variable not significant 
 
 
Hospitalisation in 
past 3 months 
    
   Yes 
   No 
 
 
 
 
Ref 
3.77 (0.03 – 7.50) 0.048 
 
 
 
 
Ref. 
3.70 (0.11 – 7.29) 0.043 
 
Time (months) 
from Diagnosis to 
starting ARVs. 
 
 
 
0.03 (-0.03 – 0.09) 0.346 
Variable not significant 
 
 
If uses other 
supplementary 
products 
   Yes 
   No 
 
 
 
 
Ref 
2.72 (1.41 – 6.84) 0.195 
 
Variable not significant 
 
 
Treatment Group 
ART-naïve 
ART-experienced 
 
 
Ref. 
5.22 (2.77 – 7.66) 0.000 
 
Ref. 
5.22 (2.77 – 7.66) 0.000 
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Table 10 above shows there was a statistically significant difference in QoL 
scores between participants who had had a hospital admission within the past 
three months and those who had not – with non-hospitalised individuals having 
3.70 points higher QoL scores than individuals who had been hospitalised. Other 
factors: length of time on ART, being on tuberculosis treatment, being on 
tuberculosis prevention therapy, having been treated before for tuberculosis, the 
type of caregiver at home, time from HIV diagnosis to starting ARTs, and the use 
of self-prescribed supplementary products were not statistically associated with 
QoL scores.  
Table 11: Univariate and multivariate regression models for QoL scores for 
variables on patient satisfaction with Information given, and satisfaction with Care 
given, for patients on ART in Gaborone. 
 
Satisfaction Level 
 
Study Group 
Univariate Model 
Coeff. (95% ci) p-value 
Multivariate Model 
Coeff. (95% ci) p-value 
 
 
Information given 
 
Not satisfied 
Low satisfaction 
Mod. Satisfaction 
High satisfaction 
 
 
 
 
Ref 
-0.06 (-16.44 – 16.31) 0.994 
-1.76 (-14.70 – 11.18) 0.789 
0.57 (-12.20 – 13.34) 0.930 
 
Variable not significant 
 
 
Care given 
 
Not satisfied 
Low satisfaction 
Mod. Satisfaction 
High satisfaction 
 
 
 
 
Ref. 
-11.58 (-27.05 – 3.89) 0.142 
-5.00 (-18.96 – 6.96) 0.363 
-4.33 (-17.04 – 8.39) 0.503 
 
Variable not significant 
 
Treatment Group 
ART-naïve 
ART-experienced 
 
 
Ref. 
5.22 (2.77 – 7.66) 0.000 
 
Ref. 
5.22 (2.77 – 7.66) 0.000 
 
Table 11 the two factors of [the patient’s level of satisfaction with information 
given by health workers] and [the level of satisfaction with the care given by 
health workers] - were not statistically associated with QoL scores. 
  
32
Table 12: Disease symptoms and lab.  factors associated with QoL for patients 
on ART in Gaborone. Univariate and multivariate regression models for QoL.  
Symptom / Marker  Univariate Model 
Coeff. (95% ci) p-value 
Multivariate Model adjusted for Treatment 
Group 
Coeff. (95% ci) p-value 
Loss of weight 
Yes 
No 
 
Diarrhea 
Yes 
No 
 
Cough 
Yes 
No 
 
Difficulty in 
breathing 
Yes 
No 
 
Night sweats 
Yes 
No 
 
Feet pains 
Yes 
No  
 
Fever or chills 
Yes 
No 
 
Other symptoms 
Yes 
No 
 
 
Ref 
6.50 (4.13 – 8.87) 0.000 
 
 
Ref 
11.60 (6.72 – 16.49) 0.000 
 
 
Ref 
4.55 (1.80 – 7.31) 0.001 
 
 
 
Ref 
6.68 (3.62 – 9.75) 0.000 
 
 
Ref 
7.19 (4.67 – 9.70) 0.000 
 
 
Ref 
7.14 (4.80 – 9.47) 0.000 
 
 
Ref 
2.60 (-0.11 – 5.31) 0.060 
 
 
Ref 
1.73 (-0.87 – 4.33) 0.192 
 
 
 
5.20 (2.44 – 7.97) 0.000 
 
 
 
10.11 (5.30 – 14.93) 0.000 
 
 
 
3.45 (0.71 – 6.19) 0.014 
 
 
 
 
6.02 (3.04 – 9.00) 0.000 
 
 
 
6.30 (3.80 – 8.81) 0.000 
 
 
 
6.76 (4.50 – 9.01) 0.000 
 
Variable not significant 
 
 
 
Variable not significant 
 
 
Viral Load 
(copies/ml) 
   
CD4 (cells/ml) 
 
 
Hemoglobin (g/dl)  
 
 
Treatment Group 
 ART-naive 
 ART-experienced 
 
 
-5.86e-07 (-0.000 – 0.000) 
0.955 
 
0.01 (0.01 – 0.02) 0.004 
 
 
0.64 (0.16 – 1.12) 0.009 
 
 
 
Ref 
5.22 (2.77 – 7.66) 0.000 
 
Variable not significant 
 
 
0.00 (-0.01 – 0.02) 0.637 
 
 
0.30 (-0.21 – 0.81) 0.246 
 
 
 
 
5.22 (2.77 – 7.66) 0.000 
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From table 12 on previous page we note the following statistically significant 
observations: Those who did not experience weight loss having 5.20 points 
higher QoL scores, participants without diarrhoea had 10.11 points higher QoL 
scores, those without cough had 3.45 points higher QoL scores, those without 
difficulty in breathing had 6.02 points higher QoL scores, those without night 
sweats had 6.30 points higher QoL scores, and those without feet pains had 6.76 
higher QoL scores. 
Laboratory disease markers: Changes in CD4 cell count, Haemoglobin level, and 
Viral do not have any statistically significant impact on QoL in multivariate model.  
Study Group: Being on ART results in a statistically significant 5.22 point 
improvement in HRQoL scores compared to those participants not on ART.  
‘Super’ Multivariate Regression Model 
From above multivariate models the following 9 statistically significant factors 
were selected to be run in a ‘super’ (non-stepwise) multivariate model:  
1. Marital status 
2. Education level  
3. Study group 
4. (No) Recent hospitalisation 
5. (No) Loss of weight 
6. (No) Diarrhoea  
7. (No) Cough  
8. (No) Difficulty in breathing 
9. (No) Night sweats 
10. (No) Feet pains   
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Table 13: Factors identified as predictors of QoL of HIV patients in Gaborone. 
Predictor factor Univariate  
Coeff. (95% ci) p-value 
Multivariate 
Coeff. (95% ci) p-value 
Absence of recent hospitalisation 3.77 (0.03 – 7.50) 0.048 3.31 (0.26 – 6.36) 0.033 
Absence of loss-of-weight  6.50 (4.13 – 8.87) 0.000 2.29 (-0.19 – 4.76) 0.070 
Absence of diarrhoea 11.60 (6.72 – 16.49) 0.000 8.73 (4.43 – 13.04) 0.000 
Absence of night sweats  7.19 (4.67 – 9.70) 0.000 3.91 (1.58 – 6.24) 0.001 
Absence of feet pains  7.14 (4.80 – 9.47) 0.000 6.43 (4.35 – 8.51) 0.000 
Being on ART 5.22 (2.77 – 7.66) 0.000 1.97 (-0.42 – 4.35) 0.106 
 
From table 13 above we see the following by examining the coefficients: relief of 
diarrhoea gives the highest increase in QoL score, followed by relief of feet pains 
and night-sweats. Effect of ‘hospitalization’ and ‘feet pains’ remains almost 
constant whether on their own or when combined with other factors. Univariate 
effect of ‘weight-loss’ and ‘being on ART’ is almost halved when these two 
variables are combined with other variables 
 
Discussion 
  
This study was able to successfully obtain data from 200 patients attending the 
Bontleng ARV clinic. Mean age of participants was 36 years with more than half 
being single. Unemployment rate was high at 36%, though 85% had some form 
of primary or secondary level education. Almost a quarter were on TB treatment. 
The overall QoL summary score was significantly higher in ART-experienced 
group, with ART-experienced patients reporting fewer disease symptoms as 
compared to the ART-naïve patients. Higher CD4 and Hb levels were also noted 
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in ART-experienced patients. Multivariable regression model identified the 
absence of recent hospitalization, weight loss, diarrhea, night sweats, and feet 
pains are the best predictor of higher QoL. 
 
This study was able to obtain current information on the socio-demographic 
characteristics of patients attending this ARV treatment site. We are thus able to 
provide a clear profile of the ‘typical’ patient attending these clinics. 
 
There are more women than men attending this clinic. The highest age-specific 
HIV prevalence rate in Botswana is found in women aged 30 - 34 years. All 
available surveillance data indicate prevalence of over 40% in this group of 
women (7). Average age for participants starting treatment is 35 years, and that 
of participants already on treatment is 36 years. Of interest to note is that QoL of 
patients on HAART improves regardless of sex, age, work-skills level, or 
employment status. 
 
In keeping with results of better HRQoL amongst participants established on 
ARVs, we notice higher employment levels amongst this group. From this study 
we cannot conclude the temporal sequence of these events: Does the improved 
general wellbeing of patients make them able to go out and find jobs, or does the 
fact of getting employment further improve their quality of life. The answer is 
probably a bit of both. 
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It is known that unequal and abusive relationships or lack of stable mature 
relationships play a role in the spread of HIV. Most respondents in this study are 
either single or co-habiting. For women many of these relations with the opposite 
sex are forged based on economic need and are thus frequently open to abuse 
with high incidence of concurrent partners, and therefore high rates of HIV 
transmission. There was no statistical difference in marital status between the 
two study groups, however, participants who reported to be separated tended to 
report a better QoL score. More studies are needed to investigate how social and 
interpersonal relationships impact treatment adherence and QoL in HIV patients. 
 
In both study groups we notice education levels of either primary or secondary 
school for most respondents. We also note a general absence of work skills that 
can be used to acquire employment. In Botswana Primary school is free, while 
secondary school is highly subsidised by government. Thus general education to 
secondary level is the norm rather than the exception. Post secondary work skill 
acquisition is however the prerogative of the individual and the pressure to get an 
unskilled job is much higher than the desire to spend more years in training so as 
to acquire more skills. 
 
All study participants were able to enrol for treatment with CD4 count results only. 
All treatment naïve participants interviewed did not have baseline Viral Load 
results. All treatment experienced participants however did have these results, 
with median VL being 400 copies/ml. Treatment guidelines aim for VL of < 400 
copies/ml in 3 months, and undetectable ( < 50 copies/ml) in six months time of 
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ARV treatment (10). Laboratory results frequently report VL at 400 copies/ml, and 
not lower, after six months of treatment, as this is the thresh-hold of lab 
equipment detection.  
 
ART-naïve patients had mean CD4 count of 114, compared to the much higher 
276 for ART-experienced patients. HB levels are also on average higher in ART-
experienced at 10.9 compared to 8.9 in ART-naïve. There is thus a strong 
association between improvement in these indices and the fact of being on ART. 
 
This study showed that with an average of 20 months of HAART, HIV patients in 
Botswana showed significantly higher scores in all constructs of HRQoL (except 
for Role Functioning) as compared to those just starting HAART. This is in 
keeping with other findings in other populations (2). Summary overall score 
(PHS) is also higher in individuals established on HAART. Thus being on anti-
retroviral treatment is associated with one having a higher QoL score for almost 
all QoL constructs, and having higher overall scores.  
 
It is thus very feasible to have these assessments incorporated in both the 
baseline and follow-up assessments of HIV patients attending treatment clinics. 
As demonstrated Hughes J et al (18) in their South African study on the use of 
HRQoL to inform health care providers about the potential use of rehabilitation 
interventions in the management of people living with HIV/AIDS, it is possible to 
do HRQoL studies in an African context and obtain valid results. 
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A systematic review of HRQoL studies (23) reveals that these scores do not 
always correlate with disease stage or health indices, and that disease symptoms 
have a greater impact on HRQoL than measured health indices. This study 
mirrors these same findings, in that although there were significant differences in 
CD4 cell count and Hb levels between treated and untreated patients, these 
indices have no statistical significant effect on HRQoL scores.  
Impact of Symptoms 
Higher QoL measurements are observed in: 
a) Patients who did not report a recent hospital admission,  
b) Those who did not experience weight loss, and  
c) In those without certain disease symptoms (diarrhea, cough, difficulty in 
breathing, night sweats, and feet pains).  
 
This study compares well with previous studies done elsewhere (17) (12) where 
adverse disease symptoms were significantly related to low HRQoL. Importantly 
for our study population these symptoms are amenable to clinical intervention. 
Thus any HRQoL assessments in these patients must always include details of 
all patient-reported symptoms.  
 
This study shows that with or without use of ART, HIV patients in Gaborone, 
Botswana, respond very well in terms of improvement of measured HRQoL when 
certain disease symptoms are addressed and treated. Therefore clinicians in HIV 
treatment clinics in Botswana must devise strategies to make the management of 
symptoms a high priority.  
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Limitations 
 
This study was conducted in an urban setting with generally high level of 
unemployment and other urban pressures impacting respondents. These factors 
will in themselves contribute to a low baseline QoL for respondents).This 
population may inherently be different from a rural population. The ARV program 
is being rolled out to the whole of Botswana, including rural areas, we thus 
cannot say with certainty that similar results as in this study will be seen in other 
areas of the country. 
 
Due to time limits, logistical difficulty and lack of a sampling frame the researcher 
was unable to obtain a completely random sample of participants to interview. 
Though we also did not in any way ‘select’ those to interview, but relied on self-
selected participants. Point of note is that those who volunteered may also in 
some way be quite different from other HIV patients (maybe more sick, or more 
health conscious, etc). 
 
The design of the study could ideally been done using a ‘before’ and ‘after’ 
methodology, i.e interviewing the same participants after several months on 
HAART. But this was not feasible due to time constraints and a possible problem 
with retention of participants due to the researcher’s limited financial resources. 
The treatment-experienced group may have been over-represented by ‘hardier’ 
HIV survivors and not necessarily all patients on HAART.  The researcher 
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however believes that the present design has also given us sufficient data to be 
able to comment with some degree of reliability. 
 
The researcher did not attempt to do clinical staging of HIV disease amongst any 
of the participants due to capacity limitations. Thus the participants may all have 
been starting treatment at different stages of the disease, with some being more 
ill than others. Disease stage-ing would have allowed a more accurate statistical 
analysis of results based on initial disease category. 
 
This was not a blinded study, and in the consenting process participants were 
clearly told what the study was about before they agreed to be interviewed. It is 
possible that the awareness that quality of life was being assessed may well have 
affected their responses 
 
In this cross-sectional study it is difficult to assess the temporal relationship 
between the explanatory variables and measured QoL scores. Thus we can only 
conclude on associations rather than causality. 
 
Conclusions and Recommendations 
This study concludes that it is feasible to conduct quality of life assessments in a 
health intervention program outside of pure clinical research settings. Reliable 
and valid results can be obtained, and these can be used to inform policy on the 
management of patients. Incorporation of these assessments in clinical programs 
should be seriously considered.  
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Death rates can no longer be the sole measurement of outcome for patients on 
ARVs (12). This is particularly the case in Africa, where with the advent and 
success of mass HAART programs, other outcomes such as HRQoL should 
become relevant, more so that validated tools are now readily available. 
 
Symptoms in patients on HAART maybe due to HIV disease itself, or may be due 
to side effects of drugs. Regardless of underlying cause, these symptoms greatly 
impact on QoL. 
 
This study showed that in this group of patients symptoms and previous 
hospitalisation are important determinants of physical health. The introduction of 
new antiretrovirals with fewer side effects, and the inclusion of a continuum of 
care that includes assessment of symptoms and socio-economic data should 
favour the beneficial impact of HAART on Health Related Quality of Life. 
 
This researcher concurs with the commentary (19) of the HIV/AIDS palliative care 
workgroup which notes that HIV patients now have a long life expectation, and 
thus more effort must be directed at maximising their disease-free interval, with 
systematic research efforts to evaluate effectiveness of various supportive 
therapies. 
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Specific recommendations: 
1. Quality of life assessments should included in the regular follow-up of 
patients on HAART. 
2. There should clear tabulated documentation and management of 
symptoms of patients in ARV programs. 
3. Standardised symptoms treatment guidelines should be developed and 
availed for all health personnel managing various HIV-related symptoms. 
4. Aggressive management of illnesses in early stages should be done in 
order to reduce episodes of hospitalisation. 
5.  Introduction of newer antiretroviral therapies with fewer side effects 
should be pursued. 
6. Adaptation of HRQoL instruments to suit local conditions in Africa. 
7. Further research as outlined below is necessary. 
 
Suggestions for further research 
 
1. Operational research into methods of incorporating deliberate symptom 
mitigation in the management of HIV patients. 
2. Head to head comparison of the impact of various HAART regimens on 
the QoL of HIV patients in Botswana. 
3. Effect of other alternative therapies including traditional medicines on QoL 
of HIV patients. 
4. To determine other social and cultural factors that influence adherence to 
HAART. 
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APPENDIX A 
Item Scoring 
 
Item Scoring, Calibration and Summing (16) 
 
Step 1:  
Data Cleaning, checking for any missing values, and reconciling from the 
questionnaire. 
 
Step 2:  
Re-calibration of one item (Q15 under Health Perceptions). In the MOS it was 
decided that the distance between responses was unequal and they should be 
adjusted in scoring the item, and then re-coding it by reversal so that high scores 
reflect favourable health. Thus 1  5, 2  4.36, 3  3.43, 4  1.99, 5  1. 
 
Step 3: 
All questions and items are scored so that a high score defines a more 
favourable health state. Some items thus needed to be reverse scored 
(Questions 11, 13, 15, 16, 17, and 21). This facilitates consistent comparison. 
 
Step 4: 
Transforming each item linearly to a 0  100 possible range. The lowest and 
highest scores were thus set at 0 and 100 respectively. Transformation formulas 
were used for this. 
 
Step 5: 
Deriving the final score per scale by simply averaging scores for items in the 
same scale as all items in a given scale have roughly equivalent relationships to 
the underlying HRQL concept being measured. 
Thus: 
1. Physical Functioning: average scores for questions 1  6. 
2. Role Functioning (work): average scores for questions 7  8. 
3. Social Functioning (activities): average scores for question 9. 
4. Mental Health Index: average scores for questions 10 14. 
5. Health Perceptions: average scores for questions 15 19. 
6. Pain: average scores for questions 20  21. 
 
 
Summary Scores 
 
PHS Formulae 
 
PHS = [ (((mh – 69.2284314)/18.8444325)*-.13017) + (((pf – 
80.4395425)/24.2176719)*.34370) + (((pn – 64.7941176)/28.8807702)*.31854) + 
(((rf – 73.1371549)/40.7722411)*.29617) + (((sf – 
84.6862745)/21.2559432)*.22165) + (((gh – 56.792402)/24.550145)*.17829) ] 
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APPENDIX B - 1 
Questionnaire 
 
Questionnaire Number: ________ Date of Interview: ____________ 
 
1. Respondents: Sex: Male □         Female □ 
 
2. Respondents: Age: __________________________________ 
 
3. Length of time on ARVs: ___________years and ________months 
 
4. Employment status: 
 
Yes (regular job)   □  
   Yes (temporary jobs)  □ 
No (not working)   □ 
   Self Employed   □ 
 
5. If currently on full TB treatment: 
 
Yes  □  
   No  □ 
   Don’t Know □ 
 
6. If currently on TB prevention (IPT) medicines:     
   Yes  □ 
   No  □ 
   Don’t know □ 
      
7. Marital status: Married  □ 
   Living with partner □ 
   Single   □ 
Separated  □ 
Widowed/widower □ 
   Divorced  □ 
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8. Closest caregiver (treatment buddy or ‘mompati’) 
 
   Immediate family member □ 
   Other relative  □ 
Friend    □ 
Other (specify)  □__________________ 
   None    □ 
 
9. Education level (highest): write actual level (e.g. std 6) ___________________ 
    
 
10. Work skills level  
   Not skilled  □ 
   Semi-skilled  □ 
   Full trade skill □  
   Professional  □ 
  
11. Number of years since HIV diagnosis: _______________ 
 
12. Any Hospitalisation during the past 3 months? 
   Yes □    
No □ 
 
13. Previous history of TB treatment 
   Yes  □ 
   No  □ 
   Don’t know □ 
 
 
14. Level of satisfaction with information from health care providers 
 
1. 
No info. 
provided 
2. 
Not satisfied 
3. 
Low 
satisfaction 
4. 
Moderate 
satisfaction 
5. 
High 
satisfaction 
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15. Level of satisfaction with treatment provided at this clinic. 
 
 
1. 
Not satisfied 
2. 
Low satisfaction 
3. 
Moderate 
satisfaction 
4. 
High satisfaction 
 
FOOD SUPPLEMENTS 
 
16. Are you taking any other nutritional supplements, vitamins or “immune 
boosters” 
  
 Yes □ (if yes go to Q 16)     No □ (if no jump Q16, go to Q 17) 
 
17. Give names of supplements/”immune booster” you have been using: 
 
 __________________________________________________ 
 
SYMPTOMS: Which of the following problems do you have at present: 
 
18. Loss of weight    □ 
19. Diarrhoea     □ 
20. Cough     □ 
21. Difficulty in breathing   □ 
22. Sweating at night    □ 
23. Feet pains and /or numbness  □ 
24. Fever or  Chills (feeling cold) □ 
25. None of the above    □ 
 
OBTAIN FROM MEDICAL RECORDS 
 
26. Last recorded HIV Viral Load: ____________________ 
    
27. Last recorded CD4 count: ________________________ 
 
28. Last recorded Hb (haemoglobin) level: __________________ 
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APPENDIX B - 2 
MOS-HIV Short Form Questionnaire 
 
 
 
Physical Functioning (Physical Health) 
These questions concern some problems you may have to deal with because of your illness. 
 
 
Does your illness limit you in these activities? 
 
INSTRUCTIONS:   For Q1 to Q8, insert clearly either [1] or [2] or [3] in the box where; 
 
        [1] = Yes. Limited a lot. 
        [2] = Yes, Limited a little. 
        [3] = No. Not limited at all 
 
ACTIVITIES 
 
1. Vigorous activities such as running, lifting heavy objects, sports activities?  □ 
 
2. Moderate activities like moving a table or carrying two full bags of groceries?  □ 
 
3. Walking uphill or climbing 10 steps without resting?    □ 
 
4. Bending, Kneeling, or stooping?       □ 
 
5. Walking from your house to nearest taxi/combi stop?    □ 
 
6. Eating, dressing, bathing or using the toilet?     □ 
 
 
Role Functioning (Daily Activities) 
These questions are about your regular daily activities. 
 
 
7. Does your health keep you from working at a job, doing work around the house or going 
to school?         □ 
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8. Have you been unable to do certain kinds or amounts of work, housework or schoolwork 
because of your health?        
 □ 
 
 
 
Social Functioning (Social Activities) 
The next question asks about your social activities. 
 
 
 
 
9. How much of the time, during the past one month has your health limited your social 
activities (for example: visiting friends, relatives, etc)? 
 
                                                                                              (Circle one) 
 
All of the time……………………………………………………………1 
 
Most of the time…………………………………………………….. 2 
 
A good bit of the time………………………………………….. 3 
 
Some of the time……………………………………………………. 4 
 
A little of the time…………………………………………………… 5 
 
None of the time…………………………………………………….. 6 
 
 
 
 
Mental Health (Your Feelings). 
 
 
 
 
10. How much of the time, during the past month, have you been a very nervous person? 
 
 
                                                                                              (Circle one) 
 
All of the time……………………………………………………………1 
 
Most of the time…………………………………………………….. 2 
 
A good bit of the time………………………………………….. 3 
 
Some of the time……………………………………………………. 4 
 
A little of the time…………………………………………………… 5 
 
None of the time…………………………………………………….. 6 
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11. During the past month, how much of the time have you felt calm and peaceful? 
 
 
                                                                                              (Circle one) 
 
All of the time……………………………………………………………1 
 
Most of the time…………………………………………………….. 2 
 
A good bit of the time………………………………………….. 3 
 
Some of the time……………………………………………………. 4 
 
A little of the time…………………………………………………… 5 
 
None of the time…………………………………………………….. 6 
 
 
12. How much of the time, during the past month, have you felt downhearted and blue? 
 
                                                                                              (Circle one) 
 
All of the time……………………………………………………………1 
 
Most of the time…………………………………………………….. 2 
 
A good bit of the time………………………………………….. 3 
 
Some of the time……………………………………………………. 4 
 
A little of the time…………………………………………………… 5 
 
None of the time…………………………………………………….. 6 
 
 
13. During the past month how much of the time have you been a happy person? 
 
                                                                                              (Circle one) 
 
All of the time……………………………………………………………1 
 
Most of the time…………………………………………………….. 2 
 
A good bit of the time………………………………………….. 3 
 
Some of the time……………………………………………………. 4 
 
A little of the time…………………………………………………… 5 
 
None of the time…………………………………………………….. 6 
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14. How much of the time, during the past month, have you felt so down in the dumps that 
nothing could cheer you up? 
 
                                                                                              (Circle one) 
 
All of the time……………………………………………………………1 
 
Most of the time…………………………………………………….. 2 
 
A good bit of the time………………………………………….. 3 
 
Some of the time……………………………………………………. 4 
 
A little of the time…………………………………………………… 5 
 
None of the time…………………………………………………….. 6 
 
 
 
Health Perceptions (Your Health) 
Next are some general questions about your health and health-related matters. 
 
 
15. In general would you say your health is: 
 
                                                                                              (Circle one) 
 
Excellent…….………………………………………………………… 1 
 
Very good…….……………………………………………………..  2 
 
Good………………………………………………………………………. 3 
 
Fair………….……………………………………………………………... 4 
 
Poor…………….…………………………………………………………. 5 
 
 
 
16. Your health is excellent…. 
 
 
                                                                                              (Circle one) 
 
Definitely true………………………………………………………………… 1 
 
Mostly true………………………………………………………………………. 2 
 
Not sure…………………………………………………………………………….3 
 
Mostly false…………………………………………………………………….. 4 
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Definitely false…………………………………………………………………. 5 
 
 
17. You are as healthy as anybody you know 
(Circle one) 
 
Definitely true………………………………………………………………… 1 
 
Mostly true………………………………………………………………………. 2 
 
Not sure…………………………………………………………………………….3 
 
Mostly false…………………………………………………………………….. 4 
 
Definitely false…………………………………………………………………. 5 
 
 
 
18. You are somewhat ill 
 
(Circle one) 
 
Definitely true………………………………………………………………… 1 
 
Mostly true………………………………………………………………………. 2 
 
Not sure…………………………………………………………………………….3 
 
Mostly false…………………………………………………………………….. 4 
 
Definitely false…………………………………………………………………. 5 
 
 
19. You have been feeling bad lately. 
 
(Circle one) 
 
Definitely true………………………………………………………………… 1 
 
Mostly true………………………………………………………………………. 2 
 
Not sure…………………………………………………………………………….3 
 
Mostly false…………………………………………………………………….. 4 
 
Definitely false…………………………………………………………………. 5 
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PAIN 
 
 
20. In the past month, have you had any bodily pain?      
 
(Circle one) 
 
Yes…………………………..…………………………………………………………1 
 
No……..…………………………………..……………………………………………2 
 
 
IF yes, was the pain: 
 
(Circle one) 
 
Very Mild………………………………………………………………….………1 
 
Mild…………………………………………………………………………………2 
 
Moderate……………………………………………………………………………3 
 
Severe………………………………………………………………………………4 
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APPENDIX C 
Potential Participant Information Sheet and Informed Consent Form 
 
Dumelang! Good day to you Sir / Madam. I am Dr Evans Buliva from 
the Medical School of the University of the Witwatersrand in South 
Africa. I am doing a study to find out how people who are sick with 
HIV are coping with their illness. 
 
I will give you an outline of how the study will be done. I do request 
and invite you to consider participating in the study. 
 
For the study I will need approximately 30 minutes of your time. I will 
ask you about 40 simple questions following the list of questions that I 
have with me. I will also ask to see your medical cards so as to obtain 
your last recorded laboratory results of CD4 count and amount of 
virus in the blood.  
 
I will require nothing else from you apart from your time to answer 
simple questions which I will read out to you. In case I notice 
something seriously wrong with your health I shall immediately refer 
you to the attending doctors at the clinic. If you require any more 
information you may contact me (Dr. Buliva) at cell 71319225. 
 
The Information you provide me is strictly confidential, and the 
personal answers you provide to me will not be shared even with the 
clinic staff. On your questionnaire will be recorded a number only and 
nobody will be able to identify your answers with you personally. 
 
This study is completely voluntary and you may withdraw at any time 
without having to give a reason. There is absolutely no risk or penalty 
for withdrawing from the study and you will continue receiving 
assistance from this clinic as usual. 
 
Some of the questions are sensitive and require personal answers 
from you. If you are disturbed by any question you have the choice 
not to answer, and you are free to stop the interview at any time. 
 
If you are happy and willing and accept to take part in the study 
please read and sign the attached consent form. Thank you. 
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CONSENT FORM 
 
I agree to participate in the study as outlined in the information sheet. 
 
Questionnaire No._______________________ 
 
Signature:______________________________ 
 
Date:__________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
58
APPENDIX D 
Wits ethics & Research committee certificate 
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APPENDIX E - 1 
Botswana Ministry of health ethics certificate 
 
 
 
  
60
APPENDIX E - 2 
Botswana Ministry Of Health Ethics Certificate - Renewal 
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APPENDIX F 
Permission letter from Gaborone City Council Health Dept 
 
 
